SCHEMBL884182

SCHEMBL884182

O=[PH](O)OC(CCCc1ccc(-c2ccccc2)cc1)S(=O)(=O)O.[KH]

nearest known ligand 0.48

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
FDFT1 P37268 4/20 0.46
MMP12 P39900 4/20 0.40
MMP13 P45452 3/20 0.40
MMP8 P22894 1/20 0.40
MGLL Q99685 1/20 0.40
MMP2 P08253 1/20 0.40
MMP9 P14780 1/20 0.40
MMP14 P50281 1/20 0.40
HDAC2 Q92769 2/20 0.39
FFAR1 O14842 1/20 0.39
HDAC1 Q13547 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL884086 0.88 FDFT1 (0.47) FDFT1
SCHEMBL884025 0.87 FDFT1 (0.50) FDFT1MMP12MMP13MMP8FFAR1
SCHEMBL884176 0.81 FDFT1 (0.49) FDFT1MMP8MMP2MMP9
SCHEMBL2066393 0.79 FDFT1 (0.54) FDFT1
SCHEMBL4294846 0.78 FDFT1 (0.55) FDFT1
SCHEMBL2066723 0.77 FDFT1 (0.57) FDFT1
SCHEMBL10066450 0.75 FDFT1 (0.52) FDFT1MMP12MMP13MMP2MMP9
Potassium Ion SCHEMBL884183 0.74 FDFT1 (0.59) FDFT1
SCHEMBL23752399 0.72 FDFT1 (0.60) FDFT1
SCHEMBL8946999 0.72 FDFT1 (0.60) FDFT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090306021-A1 ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-12-10 US claimed
JP-2009541210-A 2009-11-26 JP claimed
EP-2020857-A2 ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS The Regents of the University of California (US) 2009-02-11 EP claimed
WO-2007133712-A2 ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-11-22 WO claimed
US-8778913-B2 Antimicrobial compositions for treating microbial infections THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-07-15 US disclosed
US-20140154302-A1 ANTIMICROBIAL COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS THE UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN (US) 2014-06-05 US disclosed
US-8148352-B2 Antimicrobial therapy for bacterial infections THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-04-03 US disclosed
US-20090306021-A1 ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-12-10 US disclosed
EP-2020857-A2 ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS The Regents of the University of California (US) 2009-02-11 EP disclosed
WO-2007133712-A2 ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306021-A1 ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS SERPINB1, CUTA, SRRT FDFT1 260/4885MMP12 106/4885MMP13 522/4885
US-20140154302-A1 ANTIMICROBIAL COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS MPO, CUTA, STING1 FDFT1 368/4885MMP12 99/4885MMP13 409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.